Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for advanced cervical cancer: AK104 combo shows promise in phase 3 trial

NCT ID NCT04982237

First seen Nov 19, 2025 · Last updated May 23, 2026 · Updated 26 times

Summary

This phase 3 study tests whether adding the drug AK104 to standard chemotherapy (with or without bevacizumab) helps people with persistent, recurrent, or metastatic cervical cancer live longer without their disease worsening. About 445 women who have not had prior systemic therapy for advanced disease are participating. The main goals are to see if the combination improves progression-free survival and overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Anhui Provincial Hospital

    Hefei, China

  • Fudan University Shanghai Cancer Center

    Shanghai, 200032, China

  • The Second Affiliated Hospital,Anhui Medical University

    Hefei, China

  • Women's Hospital School Of Medicine Zhejiang University

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

Conditions

Explore the condition pages connected to this study.